U.S. Approves First Self-Administered Nasal Flu Vaccine
In a groundbreaking move, the U.S. Food and Drug Administration (FDA) announced on Friday the approval of the first nasal spray flu vaccine for self-administration. Starting next fall, AstraZeneca’s FluMist—previously available only through healthcare providers since its 2003 authorization—will be accessible directly to consumers via online pharmacies.
The needle-free vaccine offers a new level of convenience and could potentially increase vaccination rates, which have declined by 3.3 percent since the 2020-21 season. FluMist will be shipped to individuals following a screening assessment, enabling adults over 18 to administer the vaccine to themselves or to others. It is approved for use in people aged two to 49 years.
“Today’s approval of the first influenza vaccine for self- or caregiver-administration provides a new option for receiving a safe and effective seasonal influenza vaccine, potentially with greater convenience, flexibility, and accessibility for individuals and families,” said Peter Marks, a top FDA official.
The self-use approval of FluMist comes at a critical time as seasonal influenza continues to pose a significant global health risk. According to the World Health Organization, seasonal flu causes around one billion infections annually, resulting in up to 650,000 deaths worldwide.
The introduction of an at-home vaccination option could be a game-changer in public health efforts to combat influenza. A recent survey indicates that such options could boost vaccine uptake, an essential factor in preventing widespread outbreaks.
FluMist is based on a weakened form of the live influenza virus, administered as a nasal spray, eliminating the need for injections. This method may appeal to those who are hesitant about needles, thereby increasing the likelihood of vaccination.
The FDA’s approval reflects a broader trend toward increasing accessibility and convenience in healthcare, leveraging technology and new delivery methods to reach more people. As the world continues to navigate health challenges, innovations like self-administered vaccines could play a vital role in global health strategies.
Reference(s):
cgtn.com
